Citius Pharmaceuticals (CTXR) Moody Capital Disruptive Growth & Life Science Conference summary

Company structure and history

• Two entities: one focused on pharmaceuticals, the other on oncology, both sharing management and resources.

• Significant founder investment and major capital raises, including $120 million in 2021.

• Oncology subsidiary created to launch LYMPHIR, acquired via SPAC, now trading on Nasdaq.

• 71% ownership of the oncology subsidiary, with consolidated financial reporting.

• Shared services agreement enables operational efficiency across both companies.

Product portfolio and market position

• LYMPHIR, a treatment for cutaneous T-cell lymphoma, launched with full reimbursement and broad payer acceptance.

• $7.1 million revenue in first three quarters, with 44 institutions adopting the drug and 135 health plans secured.

• Early adoption occurred before full sales force deployment; now 29 representatives are in place.

• Market size for LYMPHIR estimated at $400–500 million, with U.S. and limited international distribution.

• Rights to LYMPHIR acquired for all regions except India, Japan, and parts of Asia.

Clinical data and competitive landscape

• LYMPHIR demonstrated a 36% response rate in a 302-patient trial, with rapid and durable relief.

• Side effects are manageable, with capillary leak syndrome as the most significant.

• Competing drugs include ADCETRIS and Poteligeo, but LYMPHIR offers unique advantages in mechanism and patient response.

• Market is highly concentrated, facilitating targeted sales and distribution.

• Five-year shelf life and ex-U.S. commercialization through compassionate use programs.